The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Cambridge, Massachusetts–based InVivo’s 20-patient randomized, controlled trial aims to enhance the clinical evidence for the company’s Neuro-Spinal Scaffold.

The company designed the Neuro-Spinal Scaffold to encourage functional cells to fill a cavity that will typically develop at the site of a spinal cord injury if left untreated. The scaffold is implanted at the site of the damage within one week of spinal cord injury to support neural regeneration and cell growth.

If the platform achieves this, the structural change within the spinal cord could potentially improve sensory and motor function and lead to a better quality of life for the patient.

“Reaching full enrollment in our Inspire 2.0 study is a significant advancement in our research and development efforts towards a potential treatment for spinal cord injury,” InVivo President and CEO Dr. Richard Toselli said in a news release. “We’re grateful to the study participants, as well as the clinicians, investigators, and staff who have worked relentlessly to make this possible, and of course to our team at InVivo. We’re very excited to be continuing towards our goal of serving this patient population and expect to present topline data from the study in Q1 of 2023.”

Filed Under: Clinical Trials, Implants, Neurological, Spine Tagged With: InVivo Therapeutics

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.